SG11201809788VA - Nanoliposomal irinotecan for use in treating small cell lung cancer - Google Patents
Nanoliposomal irinotecan for use in treating small cell lung cancerInfo
- Publication number
- SG11201809788VA SG11201809788VA SG11201809788VA SG11201809788VA SG11201809788VA SG 11201809788V A SG11201809788V A SG 11201809788VA SG 11201809788V A SG11201809788V A SG 11201809788VA SG 11201809788V A SG11201809788V A SG 11201809788VA SG 11201809788V A SG11201809788V A SG 11201809788VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- lung cancer
- small cell
- cell lung
- november
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 23 November 2017 (23.11.2017) WIPO I PCT omit VIII Hot 0 VIII Nall °nom mil (10) International Publication Number WO 2017/199093 Al (51) International Patent Classification: A61K 31/4745 (2006.01) A61K 9/127 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/IB2017/000681 (22) International Filing Date: 17 May 2017 (17.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/337,961 18 May 2016 (18.05.2016) US 62/345,178 03 June 2016 (03.06.2016) US 62/362,735 15 July 2016 (15.07.2016) US 62/370,449 03 August 2016 (03.08.2016) US 62/394,870 15 September 2016 (15.09.2016) US 62/414,050 28 October 2016 (28.10.2016) US 62/415,821 01 November 2016 (01.11.2016) US 62/422,807 16 November 2016 (16.11.2016) US 62/433,925 14 December 2016 (14.12.2016) US 62/455,823 07 February 2017 (07.02.2017) US 62/474,661 22 March 2017 (22.03.2017) US Applicant: IPSEN BIOPHARM LTD. [GB/GB]; Ash Road, Wrexham Industrial Estate, Wrexham GB LL13 9UF (GB). Inventors: ADIWIJAYA, Bambang; 16 Brighton Street, Belmont, MA 02478 (US). FITZGERALD, Jonathan, Basil; 32 Magnolia Street, Arlington, MA 02474 (US). LEE, Helen; 120 Rindge Avenue, Apt. 100, Cambridge, MA 02140 (US). (74) Agent: CARPMAELS & RANSFORD; One Southamp- ton Row, London WC1B 5HA (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) (54) Title: NANOLIPOSOMAL IRINOTECAN FOR USE IN TREATING SMALL CELL LUNG CANCER FIG. 1 S N- 38 IC50( n M) 10000- 10 0 0- 100- 1 0- i- 0.1- 0.01 0 O. 0 • 0 0 0 0 0 0 00000° 0 0 0 0 0 q :3, 0 • SCLC GI Pancreas o o (57) : Novel therapies for the treatment of small cell lung cancer (SCLC) include the administration of an antineoplastic therapy consisting of liposomal irinotecan administered once every two weeks, optionally including the administration of other non- antineoplastic agents to the patient such as the administration of a corticosteroid and an anti-emetic to the patient prior to the adminis- tration of the irinotecan liposome.
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662337961P | 2016-05-18 | 2016-05-18 | |
| US201662345178P | 2016-06-03 | 2016-06-03 | |
| US201662362735P | 2016-07-15 | 2016-07-15 | |
| US201662370449P | 2016-08-03 | 2016-08-03 | |
| US201662394870P | 2016-09-15 | 2016-09-15 | |
| US201662414050P | 2016-10-28 | 2016-10-28 | |
| US201662415821P | 2016-11-01 | 2016-11-01 | |
| US201662422807P | 2016-11-16 | 2016-11-16 | |
| US201662433925P | 2016-12-14 | 2016-12-14 | |
| US201762455823P | 2017-02-07 | 2017-02-07 | |
| US201762474661P | 2017-03-22 | 2017-03-22 | |
| PCT/IB2017/000681 WO2017199093A1 (en) | 2016-05-18 | 2017-05-17 | Nanoliposomal irinotecan for use in treating small cell lung cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809788VA true SG11201809788VA (en) | 2018-12-28 |
Family
ID=59258274
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912407YA SG10201912407YA (en) | 2016-05-18 | 2017-05-17 | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| SG11201809788VA SG11201809788VA (en) | 2016-05-18 | 2017-05-17 | Nanoliposomal irinotecan for use in treating small cell lung cancer |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912407YA SG10201912407YA (en) | 2016-05-18 | 2017-05-17 | Nanoliposomal irinotecan for use in treating small cell lung cancer |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230000858A1 (en) |
| EP (1) | EP3458059A1 (en) |
| JP (3) | JP2019516693A (en) |
| KR (1) | KR20190009319A (en) |
| CN (1) | CN109640995A (en) |
| AU (1) | AU2017267449A1 (en) |
| BR (1) | BR112018072988A2 (en) |
| CA (1) | CA3023743A1 (en) |
| IL (1) | IL262656A (en) |
| MA (1) | MA45046A (en) |
| MX (1) | MX2018013873A (en) |
| PH (1) | PH12018502422A1 (en) |
| SG (2) | SG10201912407YA (en) |
| TW (1) | TWI791437B (en) |
| UA (1) | UA125646C2 (en) |
| WO (1) | WO2017199093A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| PT3337467T (en) | 2015-08-20 | 2021-01-25 | Ipsen Biopharm Ltd | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| SG10201913077QA (en) | 2015-08-21 | 2020-02-27 | Ipsen Biopharm Ltd | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin |
| BR122021024957B1 (en) | 2015-10-16 | 2023-12-12 | Ipsen Biopharm Ltd | Processes for producing a storage-stabilized liposomal irinotecan composition |
| AU2017354903B2 (en) | 2016-11-02 | 2023-04-13 | Ipsen Biopharm Ltd. | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2967961T3 (en) * | 2004-05-03 | 2024-05-06 | Ipsen Biopharm Ltd | Liposomes useful in drug administration |
| ES2550759T3 (en) * | 2007-08-17 | 2015-11-12 | Celator Pharmaceuticals, Inc. | Enhanced pharmacological platinum formulations |
| AU2013202947B2 (en) * | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
-
2017
- 2017-05-17 BR BR112018072988-4A patent/BR112018072988A2/en not_active Application Discontinuation
- 2017-05-17 SG SG10201912407YA patent/SG10201912407YA/en unknown
- 2017-05-17 EP EP17734449.6A patent/EP3458059A1/en not_active Withdrawn
- 2017-05-17 KR KR1020187035369A patent/KR20190009319A/en not_active Application Discontinuation
- 2017-05-17 JP JP2018559186A patent/JP2019516693A/en not_active Withdrawn
- 2017-05-17 CN CN201780042803.5A patent/CN109640995A/en active Pending
- 2017-05-17 UA UAA201812255A patent/UA125646C2/en unknown
- 2017-05-17 WO PCT/IB2017/000681 patent/WO2017199093A1/en unknown
- 2017-05-17 CA CA3023743A patent/CA3023743A1/en active Pending
- 2017-05-17 MX MX2018013873A patent/MX2018013873A/en unknown
- 2017-05-17 MA MA045046A patent/MA45046A/en unknown
- 2017-05-17 SG SG11201809788VA patent/SG11201809788VA/en unknown
- 2017-05-17 AU AU2017267449A patent/AU2017267449A1/en not_active Abandoned
- 2017-05-18 TW TW106116523A patent/TWI791437B/en active
-
2018
- 2018-10-28 IL IL262656A patent/IL262656A/en unknown
- 2018-11-16 PH PH12018502422A patent/PH12018502422A1/en unknown
-
2020
- 2020-05-14 JP JP2020085131A patent/JP2020117548A/en not_active Withdrawn
-
2021
- 2021-11-15 JP JP2021185609A patent/JP2022010295A/en active Pending
-
2022
- 2022-03-21 US US17/699,374 patent/US20230000858A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MA45046A (en) | 2019-03-27 |
| SG10201912407YA (en) | 2020-02-27 |
| JP2019516693A (en) | 2019-06-20 |
| WO2017199093A1 (en) | 2017-11-23 |
| KR20190009319A (en) | 2019-01-28 |
| CN109640995A (en) | 2019-04-16 |
| JP2022010295A (en) | 2022-01-14 |
| MX2018013873A (en) | 2019-02-14 |
| BR112018072988A2 (en) | 2019-04-09 |
| IL262656A (en) | 2018-12-31 |
| EP3458059A1 (en) | 2019-03-27 |
| PH12018502422A1 (en) | 2019-03-11 |
| US20230000858A1 (en) | 2023-01-05 |
| AU2017267449A1 (en) | 2018-11-15 |
| TWI791437B (en) | 2023-02-11 |
| JP2020117548A (en) | 2020-08-06 |
| CA3023743A1 (en) | 2017-11-23 |
| UA125646C2 (en) | 2022-05-11 |
| TW201740946A (en) | 2017-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809788VA (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer | |
| SG11201810161RA (en) | Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201806745RA (en) | Sulfonylureas and related compounds and use of same | |
| SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201903615WA (en) | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201804647TA (en) | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201811237WA (en) | Combination therapies | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
| SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists |